Document:

Exhibit
10.1

 

STOCK
PURCHASE AGREEMENT

 

THIS
STOCK PURCHASE AGREEMENT (this “Agreement”) is made as of the 22nd day of June 2021, by and between Omnia
Wellness Inc., a Nevada corporation (the “Company”), and DML 888 GmbH a German limited liability company (the “Purchaser”).

 

WHEREAS,
the Purchaser wishes to make an investment in the Company pursuant to the terms and conditions set forth in this Agreement.

 

NOW
THEREFORE, the parties hereby agree as follows:

 

1. Purchase
and Sale of Securities.

 

1.1. Sale
and Issuance of Common Stock. Subject to the terms and conditions of this Agreement, the Purchaser agrees to purchase and the
Company agrees to sell and issue to the Purchaser, 454,545 shares of Common Stock, par value $0.001 per share, of the Company (the
“Common Stock”) at a purchase price per share of $0.22.

 

1.2.
Closing; Delivery. The purchase and sale of the Shares shall take place remotely via the exchange of documents and signatures,
on the date hereof, or at such other time and place as the Company and the Purchaser mutually agree upon, orally or in writing (which
time and place are designated as the “Closing”).

 

1.3. Use
of Proceeds. The Company shall have broad discretion over the allocation of the proceeds from sale of the Common Stock pursuant
to this Agreement, including for working capital, general corporate purposes and the repayment of outstanding indebtedness or other
liabilities.

 

1.4. Defined
Terms Used in this Agreement. In addition to the terms defined elsewhere in this Agreement, the following terms used in this
Agreement shall be construed to have the meanings set forth or referenced below.

 

(a)
“Material Adverse Effect” means a material adverse effect on the business, assets, liabilities, financial
condition, property or results of operations of the Company.

 

(b)
“Person” means any individual, corporation, partnership, trust, limited liability company, association or other
entity.

 

(c)
“Securities Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated
thereunder.

 

(d)
“Shares” means the shares of Common Stock issued at the Closing and reflected as such on the books and records of
the Company.

 

2. Representations
and Warranties of the Company. The Company hereby represents and warrants to the Purchaser that the following representations are
true and complete as of the date of the Closing, except as otherwise indicated.

 

    	 	 	 

     

    

 

2.1
Organization, Good Standing, Corporate Power and Qualification. The Company is a corporation duly organized, validly existing
and in good standing under the laws of the State of Florida and has all requisite corporate power and authority to carry on its business
as presently conducted and as proposed to be conducted. The Company is duly qualified to transact business and is in good standing in
each jurisdiction in which the failure to so qualify would have a Material Adverse Effect.

 

2.2
Authorization. All corporate action required to be taken by the Company’s Board of Directors and stockholders in order to
authorize the Company to enter into this Agreement, and to issue the Shares at the Closing, has been taken or will be taken prior to
the Closing. All action on the part of the officers of the Company necessary for the execution and delivery of this Agreement, the performance
of all obligations of the Company under this Agreement to be performed as of the Closing, and the issuance and delivery of the Shares,
have been taken prior to the Closing. This Agreement, when executed and delivered by the Company, shall constitute valid and legally
binding obligations of the Company, enforceable against the Company in accordance with its terms except (i) as limited by applicable
bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance, or other laws of general application relating to or affecting
the enforcement of creditors’ rights generally or (ii) as limited by laws relating to the availability of specific performance,
injunctive relief, or other equitable remedies.

 

2.4 Valid
Issuance of Shares. The Shares, when issued, sold and delivered in accordance with the terms and for the consideration set forth
in this Agreement, will be validly issued, fully paid and nonassessable and free of restrictions on transfer other than restrictions
on transfer under applicable state and federal securities laws and liens or encumbrances created by or imposed by the Purchaser.
Assuming the accuracy of the representations of the Purchaser in Section 3 of this Agreement, the Shares will be issued in
compliance with all applicable federal and state securities laws.

 

2.5 Compliance
with Other Instruments. The Company is not in violation or default (i) of any provisions of its Certificate of Incorporation or
Bylaws, (ii) of any instrument, judgment, order, writ or decree, (iii) under any note, indenture or mortgage, (iv) under any
material lease, agreement, contract or purchase order to which it is a party or by which it is bound or (v) to its knowledge, of any
provision of federal or state statute, rule or regulation applicable to the Company, the violation of which would have a Material
Adverse Effect.

 

2.6 Disclosure.
The Company has made available to the Purchaser all the information reasonably available to the Company that the Purchaser has
requested for deciding whether to acquire the Shares.

 

2.7
No Other Representations or Warranties. Except for the representations and warranties contained in this Agreement, neither
the Company, nor any other Person, makes any other express or implied representation or warranty on behalf of the Company or its affiliates.
Neither the Company, nor any other Person, makes any representations or warranties to the Purchaser regarding any projection or forecast
regarding future results or activities or the probable success or profitability of the business of the Company or its affiliates.

 

    	 	 	 

     

    

 

3. Representations
and Warranties of the Purchaser. The Purchaser hereby represents and warrants to the Company, as of the date of the Closing,
that:

 

3.1
Authorization. The Purchaser has full power and authority to enter into this Agreement. This Agreement, when executed and
delivered by the Purchaser, will constitute valid and legally binding obligations of the Purchaser, enforceable in accordance with its
terms, except as limited by applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance and any other laws of
general application affecting enforcement of creditors’ rights generally, and as limited by laws relating to the availability of
specific performance, injunctive relief or other equitable remedies.

 

3.2 Purchase
Entirely for Own Account. This Agreement is made with the Purchaser in reliance upon the Purchaser’s representation
to the Company, which by the Purchaser’s execution of this Agreement, the Purchaser hereby confirms, that the Shares to be
acquired by the Purchaser will be acquired for investment for the Purchaser’s own account, not as a nominee or agent, and not
with a view to the resale or distribution of any part thereof, and that the Purchaser has no present intention of selling, granting
any participation in, or otherwise distributing the same. By executing this Agreement, the Purchaser further represents that the
Purchaser does not presently have any contract, undertaking, agreement or arrangement with any Person to sell, transfer or grant
participations to such Person or to any third Person, with respect to the Shares. The Purchaser has not been formed for the specific
purpose of acquiring the Shares.

 

3.3
Disclosure of Information. The Purchaser has had an opportunity to discuss the Company’s business, management, financial
affairs and the terms and conditions of the offering of the Shares with the Company’s management and has had an opportunity to
review the Company’s facilities. The foregoing, however, does not modify in any way the representations and warranties of the Company
in Section 2 of this Agreement or the right of the Purchaser to rely thereon.

 

3.4 Restricted
Securities. The Purchaser understands that the Shares have not been, and will not be, registered under the Securities Act, by
reason of a specific exemption from the registration provisions of the Securities Act which depends upon, among other things, the
bona fide nature of the investment intent and the accuracy of the Purchaser’s representations as expressed herein. The
Purchaser understands that the Shares are “restricted securities” under applicable U.S. federal and state securities
laws and that, pursuant to these laws, the Purchaser must hold the Shares indefinitely unless they are registered with the
Securities and Exchange Commission and qualified by state authorities, or an exemption from such registration and qualification
requirements is available. The Purchaser acknowledges that the Company has no obligation to register or qualify the Shares for
resale. The Purchaser further acknowledges that if an exemption from registration or qualification is available, it may be
conditioned on various requirements including, but not limited to, the time and manner of sale, the holding period for the Shares
(which may be 6 months or a year), and on requirements relating to the Company which are outside of the Purchaser’s control
(such as whether the Company is public and whether it was ever involved in a “reverse merger” or similar transaction),
and which the Company is under no obligation and may not be able to satisfy.

 

    	 	 	 

     

    

 

3.5
No Public Market. The Purchaser understands that no public market now exists for the Shares, and that the Company has made
no assurances that a public market will ever exist for the Shares.

 

3.6
Legends. The Purchaser understands that the Shares may be notated with one or all of the following legends:

 

“THE
SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AND HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT
WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO SUCH TRANSFER MAY BE EFFECTED WITHOUT AN EFFECTIVE REGISTRATION
STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL IN A FORM SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED UNDER
THE SECURITIES ACT OF 1933.”

 

3.7
Accredited Investor. The Purchaser is an accredited investor as defined in Rule 501(a) of Regulation D promulgated under
the Securities Act.

 

3.8
No General Solicitation. Neither the Purchaser, nor any of its officers, directors, employees, agents, stockholders or partners
has either directly or indirectly, including, through a broker or finder (a) engaged in any general solicitation, or (b) published any
advertisement in connection with the offer and sale of the Shares.

 

3.9
Residence. If the Purchaser is an individual, then the Purchaser resides in the state or province identified in the address of
the Purchaser set forth on the signature page hereto; if the Purchaser is a partnership, corporation, limited liability company or other
entity, then the office or offices of the Purchaser in which its principal place of business is identified in the address or addresses
of the Purchaser set forth on the signature page hereto.

 

4.
Miscellaneous.

 

4.1
Survival of Warranties. Unless otherwise set forth in this Agreement, the representations and warranties of the Company and the
Purchaser contained in or made pursuant to this Agreement shall survive the execution and delivery of this Agreement and the Closing
and shall in no way be affected by any investigation or knowledge of the subject matter thereof made by or on behalf of the Purchaser
or the Company.

 

4.2
Successors and Assigns. The terms and conditions
of this Agreement shall inure to the benefit of and be binding upon the respective successors and assigns of the parties. Nothing in
this Agreement, express or implied, is intended to confer upon any party other than the parties hereto or their respective successors
and assigns any rights, remedies, obligations or liabilities under or by reason of this Agreement, except as expressly provided in this
Agreement.

 

4.3
Counterparts. This Agreement may be executed in two (2) or more counterparts, each of which shall be deemed an original, but all
of which together shall constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic mail (including
pdf or any electronic signature) or other transmission method and any counterpart so delivered shall be deemed to have been duly and
validly delivered and be valid and effective for all purposes.

 

    	 	 	 

     

    

 

4.4
Titles and Subtitles. The titles and subtitles used in this Agreement are used for convenience only and are not to be considered
in construing or interpreting this Agreement.

 

4.5
Notices. All notices and other communications given or made pursuant to this Agreement shall be in writing and shall be
deemed effectively given upon the earlier of actual receipt, or (a) personal delivery to the party to be notified, (b) when sent, if
sent by electronic mail or facsimile during normal business hours of the recipient, and if not sent during normal business hours, then
on the recipient’s next business day, (c) five (5) days after having been sent by registered or certified mail, return receipt
requested, postage prepaid, or (d) one (1) business day after deposit with a nationally recognized overnight courier, freight prepaid,
specifying next business day delivery, with written verification of receipt. All communications shall be sent to the respective parties
at their address as set forth on the signature page or, or to such e-mail address, facsimile number or address as subsequently modified
by written notice given in accordance with this Subsection 4.5.

 

4.6
Amendments and Waivers. Any term of this Agreement may be amended, terminated or waived only with the written consent of the Company
and the Purchaser. Any amendment or waiver effected in accordance with this Section 4.6 shall be binding only upon the Purchaser and
each permitted transferee of the Shares held by the Purchaser, and the Company.

 

4.7
Severability. The invalidity or unenforceability of any provision hereof shall in no way affect the validity or enforceability
of any other provision.

 

4.8
Delays or Omissions. No delay or omission to exercise any right, power or remedy accruing to any party under this Agreement, upon
any breach or default of any other party under this Agreement, shall impair any such right, power or remedy of such non-breaching or
non-defaulting party nor shall it be construed to be a waiver of any such breach or default, or an acquiescence therein, or of or in
any similar breach or default thereafter occurring; nor shall any waiver of any single breach or default be deemed a waiver of any other
breach or default theretofore or thereafter occurring. Any waiver, permit, consent or approval of any kind or character on the part of
any party of any breach or default under this Agreement, or any waiver on the part of any party of any provisions or conditions of this
Agreement, must be in writing and shall be effective only to the extent specifically set forth in such writing. All remedies, either
under this Agreement or by law or otherwise afforded to any party, shall be cumulative and not alternative.

 

4.9
Entire Agreement. This Agreement constitutes the full and entire understanding and agreement between the parties with respect
to the subject matter hereof, and any other written or oral agreement relating to the subject matter hereof existing between the parties
are expressly canceled.

 

    	 	 	 

     

    

 

4.10
Governing Law; Dispute Resolution. This Agreement shall be governed by the internal law of the State of Colorado without regard
to the choice of law provisions of any jurisdiction. Each party hereto irrevocably submits to the exclusive jurisdiction of the state
or federal courts located in the City and State of Denver, Colorado for the purposes of any action or claim arising out of this Agreement
or any transaction contemplated hereby, and agrees to commence any such action or claim only in such courts. Each party further agrees
that service of any process, summons, notice or document by U.S. registered mail to such party’s respective address set forth herein
shall be effective service of process for any such action or claim. Each party irrevocably and unconditionally waives any objection to
the laying of venue of any action or claim arising out of this Agreement or the transactions contemplated hereby in such courts, and
hereby irrevocably and unconditionally waives and agrees not to plead or claim in any such court that any such action or claim brought
in any such court has been brought in an inconvenient forum. EACH PARTY HEREBY IRREVOCABLY WAIVES ALL RIGHT TO TRIAL BY JURY IN ANY ACTION,
PROCEEDING OR COUNTERCLAIM (WHETHER BASED ON CONTRACT, TORT OR OTHERWISE) ARISING OUT OF OR RELATING TO THIS AGREEMENT AND THE TRANSACTIONS
CONTEMPLATED HEREBY OR THE ACTIONS OF SUCH PARTY IN THE NEGOTIATION, ADMINISTRATION, PERFORMANCE AND ENFORCEMENT HEREOF.

 

4.11
Further Assurances. Each of the parties hereto shall, from time to time at the request of the other party, furnish the other party
such further information or assurances, execute and deliver such additional documents, instruments and conveyances, and take such other
actions and do such other things, as may be reasonably necessary or appropriate to carry out the provisions of this Agreement and give
effect to the transactions contemplated hereby and thereby.

 

[Remainder
of Page Intentionally Left Blank; Signature Page Follows]

 

    	 	 	 

     

    

 

IN
WITNESS WHEREOF, the parties have executed this Securities Purchase Agreement as of the date first written above.

 

	 	COMPANY:
	 	 	 
	 	OMNIA
    WELLNESS INC.
	 	 
	 	By:	/s/
Steve Howe
	 	Name:	Steve
    Howe
	 	Title:	Executive
    Chairman
	 	 	 
	 	PURCHASER:
	 	 
	 	DML
    888 GmbH
	 	 
	 	By:	/s/
    Daniel Mahnert-Lueg
	 	Name:	Daniel
    Mahnert-Lueg
	 	Title:	Managing
    Director

 

	 	Address:________________________________________
	 	 
	 	
	 	 
	 	E-mail/Facsimile:___________________________________Exhibit 10.1

 

 

 

June 22, 2021

 

Michael Doyle

 

		Re:	Employment Agreement

 

Dear Mike:

 

Quanterix Corporation (the “Company”) is pleased
to offer you the full-time position of Chief Financial Officer and Treasurer, reporting to me. Your start date will be on or before July
12, 2021. We are excited about the prospect of you joining our team.

 

1.                 
Base Salary: The Company will pay you a salary at an annual rate of $415,000.00, paid at a bi-weekly rate of $15,961.54,
subject to periodic review and adjustment at the discretion of the Company.

 

2.                 
Bonus: You will be eligible to receive an annual performance bonus beginning with the Company’s 2021 performance
year. Your annual bonus target will be up to $210,000.00 (the “Target Bonus”). The actual amount earned will be subject
to the achievement of the metrics and goals established by the Company. The annual bonus will be subject to approval by and adjustment
at the discretion of the Company, and the terms of any applicable bonus plan or award. Your 2021 bonus target will be determined based
on your actual base salary earned during the year.

 

3.                 
Benefits: You will be eligible to participate in the employee benefits and insurance programs generally made available to
its full-time employees, including medical insurance, dental insurance, 401K Plan and match, ESPP, Flexible Spending Account, term life
insurance, and short and long term disability insurance. Details of these benefits programs, including mandatory employee contributions,
will be made available to you when you start. You also will be eligible to receive paid vacation time. You will be eligible for up to
20 days of paid vacation per year, which shall accrue on a prorated basis. Other provisions of the Company’s vacation policy are
set forth in the policy itself.

 

4.                 
Sign-On Equity Award: You will be eligible to receive a sign-on equity award consisting of 5,530 restricted stock units
(RSUs) and 12,904 non-qualified stock options. Your sign-on equity award will vest over a four period, with one-fourth vesting on the
first anniversary of your actual start date. The remainder will vest ratably on a monthly basis over the next three years. The exercise
price of your stock options will be our closing stock price on your actual start date. Your award will also be subject to the terms of
our 2017 Employee, Director and Consultant Equity Incentive Plan and the Company’s form of award agreements. 

 

     

    	Michael Doyle
 Employment Agreement
 Page 2	 

    

 

5.              
Long Term Equity Incentive Award: You will also be eligible to receive an annual equity grant as part of the Company’s
next long term equity incentive award cycle, which we expect to commence in the first quarter of 2022. The Company will target a grant
date fair value of the annual equity awards of up to $900,000.00. The value of your award will be discretionary and will be subject to
your achievement of the metrics and goals established by the Company. Your equity grant will be subject to valuation methodologies and
other terms and conditions applicable to other similarly situated executives of the Company, and will be subject to Compensation Committee
approval.

 

6.                 
Relocation. This is a Boston-based position and you will be expected to work in the Company’s Boston area office unless
you are travelling on business. You agree to use your best efforts to establish a residence in the Boston area on or before September
15, 2021. The Company will reimburse your actual, reasonable transitional housing expenses through September 15, 2021.

 

7.              
At-Will Employment; Accrued Obligations: Your employment is “at will,” meaning you or the Company may terminate
your employment at any time for any or no reason. In the event of the termination of your employment for any reason, the Company shall
pay you the “Accrued Obligations,” defined as (1) your base salary through the date of termination; (2) an amount equal
to the value of your accrued unused vacation days; (3) the amount of any expenses properly incurred by you on behalf of the Company prior
to any such termination and not yet reimbursed; and (4) to the extent not theretofore paid or provided,
any other amounts or benefits required to be paid or provided or which you have earned under any plan or agreement of or with the Company
through the date of termination.

 

8.              
Severance: Without limiting the at-will nature of your employment relationship, if the Company terminates your employment
without Cause, or if you resign for Good Reason, the Company shall provide you with the following
termination benefits (the “Termination Benefits”): 

 

		(a)	Salary Continuation Payments. Continuation of your base salary
for a period of twelve (12) months after the date of termination (the “Severance Period”) at the salary
rate then in effect.

 

     

    	Michael Doyle
 Employment Agreement
 Page 3	 

    

 

		(b)	Target Bonus. An amount equal to your applicable annual target bonus for the year of termination,
paid in one lump sum on the Company’s next regularly-scheduled payroll date following the effective date of the separation agreement
described below.

 

		(c)	Acceleration of Sign-On Equity Award. Notwithstanding anything
to the contrary in the applicable equity plan or the award agreement applicable to your Sign-On Equity Award, any outstanding but unvested
portion of your Sign-On Equity Award that would have vested during the Severance Period had you remained employed during such time shall
accelerate and become fully-vested and exercisable as of the later of (A) the termination date, or (B) the effective date of the separation
agreement described below.

 

		(d)	Health Benefits Continuation. Continuation of group health plan benefits to the extent authorized
by and consistent with 29 U.S.C. § 1161 et seq. (commonly known as “COBRA”), with the cost of the regular premium for
such benefits shared in the same relative proportion by the Company and you as in effect on the date of termination until the earlier
of (i) the end of the Severance Period; or (ii) the date you become eligible for health benefits through another employer or otherwise
become ineligible for COBRA (“Health Benefits Continuation Payments”). Notwithstanding the above, (x) in the event
that the Severance Period extends beyond eighteen (18) months following your date of termination, or (y) if the Company otherwise determines
in its sole discretion that it cannot provide the foregoing Health Benefits Continuation Payments without potentially violating applicable
law (including but not limited to the 2010 Patient Protection and Affordable Care Act, as amended by the 2010 Health Care and Education
Reconciliation Act), the Company shall in lieu thereof provide to you a taxable monthly payment in an amount equal to the Company’s
portion of the monthly COBRA premium (as described above) that you would be required to pay to continue your group health coverage in
effect on the date of your termination (which amount shall be based on the premium for the first month of COBRA coverage), which payments
shall be made on the last day of each month regardless of whether COBRA continuation coverage remains available (i.e., in the event that
the Severance Period extends beyond eighteen (18) months following your date of termination) and shall end on the earlier of (1) the end
of the Severance Period, (2) the date you become eligible for health benefits through another employer or otherwise become ineligible
for COBRA; or (3) the last day of the twenty-fourth (24th) calendar month following your termination date.

 

If the Company terminates your employment without Cause,
or if you resign for Good Reason, and the effective date of such termination occurs within the 90 day period immediately preceding or
the twelve (12) month period immediately following a Change-in-Control (such period the “Change-in-Control Period”
and such termination a “Change-in-Control Termination”), then in addition to the Termination Benefits set forth immediately
above:

 

     

    	Michael Doyle
 Employment Agreement
 Page 4	 

    

 

Equity Acceleration. Notwithstanding anything
to the contrary in any applicable equity plan or award agreement, all of your outstanding but unvested equity awards shall accelerate
and become fully-vested and exercisable as of the later of (A) the termination date, or (B) the effective date of the separation agreement
described below, or (C) as of the Change-in-Control.

 

Notwithstanding anything to the contrary in this Agreement,
you shall not be entitled to any Termination Benefits unless (a) within 60 days of your date of termination, you first (i) enter into,
do not revoke, and comply with the terms of a separation agreement in a form acceptable to the Company, which shall include a general
release in favor of the Company and related persons and entities, and other provisions regarding non-competition, confidentiality, cooperation,
non-disparagement and the like as may be included in the Company’s then current form of separation agreement (the “Release”);
(ii) resign from any and all positions, including, without implication of limitation, as a director, trustee, and officer, that you then
hold with the Company and any affiliate of the Company; and (iii) return all Company property and comply with any instructions related
to deleting and purging duplicates of such Company property, and (b) you comply with the terms of your Non-Competition, Non-Solicitation,
Confidentiality and Assignment Agreement or any other similar agreements with the Company. The Salary Continuation Payments shall commence
within 60 days after the date of termination and shall be made on the Company’s regular payroll dates; provided, however, that if
the 60-day period begins in one calendar year and ends in a second calendar year, the Salary Continuation Payments shall begin to be paid
in the second calendar year. In the event you miss a regular payroll period between the date of termination and the first Salary Continuation
Payment, the first Salary Continuation Payment shall include a “catch up” payment.

 

For purposes of this Section:

 

“Cause” means the occurrence of any
of the following (and, if applicable, that the Company has complied with the Cause Process (hereinafter defined) following the occurrence
of a circumstance subject to the Cause Process): (i) theft, fraud, embezzlement, misappropriation of assets or property of the Company,
or material violation of your Non-Competition, Non-Solicitation, Confidentiality and Assignment Agreement; (ii) dishonesty, gross negligence,
misconduct, neglect of duties, or breach of fiduciary duty to the Company; (iii) violation of federal or state securities laws; (iv) breach
of an employment, consulting or other agreement with the Company; (v) the conviction of a felony, or any crime involving moral turpitude,
including a plea of guilty or nolo contendere; or (vi) continued, willful and deliberate non-performance by you of your duties
hereunder (other than by reason of your physical or mental illness, incapacity or disability).

 

     

    	Michael Doyle
 Employment Agreement
 Page 5	 

    

 

“Cause Process” means that (1) the
Company has reasonably determined in good faith that a “Cause” condition has occurred; (2) the Company has notified you in
writing of the first occurrence of the Cause condition within 60 days of the first occurrence of such condition; (3) you are provided
a period of 30 days following such notice (the “Cause Cure Period”) to remedy the condition; (4) notwithstanding such
efforts, the Company reasonably and in good faith determines at the end of the Cause Cure Period that the Cause condition continues to
exist; and (5) the Company terminates your employment within 30 days after the end of the Cause Cure Period. If you cure the Cause condition
during the Cause Cure Period, Cause shall be deemed not to have occurred. The Company shall not be required to follow the Cause Process
as to those conditions which it reasonably determines in good faith cannot be cured within the Cause Cure Period. For the avoidance of
doubt, you and the Company acknowledge and agree that clauses (i), (iii) and (v) cannot be cured, and shall not be subject to the requirements
of the Cause Process.

 

“Change-in-Control” means the occurrence
of any of the following events: (i) any “Person” (as such term is used in Sections 13(d) and 14(d) of the Securities Exchange
Act of 1934, as amended) becomes the “Beneficial Owner” (as defined in Rule 13d-3 under said Act), directly or indirectly,
of securities of the Company representing fifty percent (50%) or more of the total voting power represented by the Company’s then
outstanding voting securities; (ii) a change in the composition of the Company’s Board of Directors occurring within a two-year
period, as a result of which fewer than a majority of the directors are Incumbent Directors. “Incumbent Directors” will mean
directors who either (A) are directors of the Company as of the date hereof, or (B) are elected, or nominated for election,
to the Board with the affirmative votes of at least a majority of the Incumbent Directors at the time of such election or nomination (but
will not include an individual whose election or nomination is in connection with an actual or threatened proxy contest relating to the
election of directors to the Company); (iii) the consummation of a merger or consolidation of the Company, other than a merger or consolidation
which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining
outstanding or by being converted into voting securities of the surviving entity or the parent of such corporation) at least fifty percent
(50%) of the total voting power represented by the voting securities of the Company or such surviving entity or parent of such corporation,
as the case may be, outstanding immediately after such merger or consolidation; or (iv) the consummation of the sale or disposition by
the Company of all or substantially all of the Company’s assets.

 

     

    	Michael Doyle
 Employment Agreement
 Page 6	 

    

 

“Good Reason” means that you have
complied with the Good Reason Process following the occurrence of any of the following actions undertaken by the Company without your
express prior written consent: (i) the material diminution in your authority, duties and responsibilities; (ii) a material reduction in
your base salary, provided, however, that Good Reason shall not be deemed to have occurred in the event of a reduction in your base salary
that is pursuant to a salary reduction program affecting or a material portion of the similarly situated senior level employees of the
Company and that does not adversely affect you to a greater extent than such similarly situated employees; and (iii) a change in the geographic
location at which you must regularly report to work and perform services of more than thirty (30) miles, except for required travel on
the Company’s business; or (v) a material breach by the Company of any of its obligations to you under its employment agreements
with you.

 

“Good Reason Process” means that
(1) you have reasonably determined in good faith that a “Good Reason” condition has occurred; (2) you have notified the Company
in writing of the first occurrence of the Good Reason condition within 30 days of the first occurrence of such condition; (3) the Company
is provided with a period of 30 days following such notice (the “Cure Period”) to remedy the condition; (4) notwithstanding
such efforts, you reasonably and in good faith determine at the end of the Cure Period that the Good Reason condition continues to exist;
and (5) you terminate your employment within 30 days after the end of the Cure Period. If the Company cures the Good Reason condition
during the Cure Period, Good Reason shall be deemed not to have occurred.

 

9.                 
Section 280G:

 

		(a)	If any payment or benefit you would receive under this Agreement, when combined with any other payment or
benefit you receive pursuant to a Change-in-Control (for purposes of this Section, a “Payment”) would constitute a
 “parachute payment” within the meaning of Section 280G of the Internal Revenue Code of 1986, as amended (the “Code”)
and, but for this sentence, be subject to the excise tax imposed by Code Section 4999 (the “Excise Tax”), then such
Payment shall be either: (i) the full amount of such Payment; or (ii) such lesser amount (a “Reduced Payment”) as would
result in no portion of the Payment being subject to the Excise Tax, whichever of the foregoing amounts, taking into account the applicable
federal, state and local employment taxes, income taxes and the Excise Tax, results in your receipt, on an after-tax basis, of the greater
amount of the Payment notwithstanding that all or some portion of the Payment may be subject to the Excise Tax.

 

		(b)	With respect to Section 10(a), if there is more than one method of reducing the Reduced Payment amount that
would result in no portion of the Payment being subject to the Excise Tax, then the Payment shall be reduced or eliminated in the following
order: (i) cash payments; (ii) taxable benefits; (iii) nontaxable benefits; and (iv) accelerated vesting of equity awards in a manner
that maximizes the amount to be received by you.

 

     

    	Michael Doyle
 Employment Agreement
 Page 7	 

    

 

		(c)	The determination of whether Section 10(a)(i) or (ii) applies, and the calculation of the amount of the Reduced
Payment if applicable, shall be performed by a nationally recognized certified public accounting firm as may be designated by the Company
(the “Accounting Firm”). The Accounting Firm shall provide detailed supporting calculations to both the Company and
you within fifteen (15) business days of the receipt of notice from you that there has been a Payment, or such earlier time as is requested
by the Company, in a form that can be relied upon for tax filing purposes. All fees and expenses of the Accounting Firm shall be borne
solely by the Company.

 

		(d)	You may receive a Payment that is, in the aggregate, either more or less than the amount described in Section
10(a)(i) or (ii) (as applicable, an “Overpayment” or “Underpayment”). If it is finally determined
by a court of competent jurisdiction pursuant to a final non-appealable judgment, or the Internal Revenue Service, or by the Accounting
Firm upon request by either the Company or you, that an Overpayment or Underpayment has been made, then: (i) in the event of an Overpayment,
you shall promptly repay the Overpayment to the Company, together with interest on the Overpayment at the applicable federal rate from
the date of your receipt of such Overpayment until the date of such repayment; and (ii) in the event of an Underpayment, the Company shall
promptly pay an amount equal to the Underpayment to you, together with interest on such amount at the applicable federal rate from the
date such amount would have been paid to you had the provisions of Section 10(a)(ii) not been applied until the date of payment.

 

10.             
Section 409A: Anything in this Agreement to the contrary notwithstanding, if at the time of your separation from
service within the meaning of Section 409A of the Code, the Company determines that you are a “specified employee” within
the meaning of Section 409A(a)(2)(B)(i) of the Code, then to the extent any payment or benefit that you become entitled to under this
Agreement on account of your separation from service would be considered deferred compensation subject to the 20 percent additional tax
imposed pursuant to Section 409A(a) of the Code, such payment shall not be payable and such benefit shall not be provided until the
date that is the earlier of (A) six months and one day after your separation from service, or (B) your death. If any such delayed
cash payment is otherwise payable on an installment basis, the first payment shall include a catch-up payment covering amounts that would
otherwise have been paid during the six-month period but for the application of this provision, and the balance of the installments shall
be payable in accordance with their original schedule. All in-kind benefits provided and expenses eligible for reimbursement under this
Agreement shall be provided by the Company or incurred by you during the time periods set forth in this Agreement. All reimbursements
shall be paid as soon as administratively practicable, but in no event shall any reimbursement be paid after the last day of the taxable
year following the taxable year in which the expense was incurred. The amount of in-kind benefits provided or reimbursable expenses incurred
in one taxable year shall not affect the in-kind benefits to be provided or the expenses eligible for reimbursement in any other taxable
year. Such right to reimbursement or in-kind benefits is not subject to liquidation or exchange for another benefit. To the extent that
any payment or benefit described in this Agreement constitutes “non-qualified deferred compensation” under Section 409A
of the Code, and to the extent that such payment or benefit is payable upon your termination of employment, then such payments or benefits
shall be payable only upon your “separation from service.” The Company and you intend that this Agreement will be administered
in accordance with Section 409A of the Code. To the extent that any provision of this Agreement is ambiguous as to its compliance with
Section 409A of the Code, the provision shall be read in such a manner so that all payments hereunder comply with Section 409A of the
Code. It is intended that each installment of the severance payments and benefits provided under this Agreement shall be treated as a
separate “payment” for purposes of Section 409A. Neither the Company nor you shall have the right to accelerate or defer the
delivery of any such payments or benefits except to the extent specifically permitted or required by Section 409A. The Company makes no
representation or warranty and shall have no liability to you or any other person if any provisions of this Agreement are determined to
constitute deferred compensation subject to Section 409A of the Code but do not satisfy an exemption from, or the conditions of, such
Section.

 

     

    	Michael Doyle
 Employment Agreement
 Page 8	 

    

 

11.             
No Guarantee of Tax Consequences: The Company makes no guarantee of any tax consequences
with respect to any payment hereunder, including, without limitation, under Section 409A of the Code.

 

12.             
No Mitigation: In no event, except as set forth expressly in this or another agreement
signed by you, shall you be obligated to seek other employment or take any other action by way of mitigation of the amounts payable to
you under any of the provisions of this Agreement and, subject to the aforesaid exception, such amounts shall not be reduced whether or
not you obtain other employment.

 

13.             
Return of Company Property: Upon termination of employment for any reason, you shall promptly
return to the Company any keys, credit cards, passes, confidential documents or material, computer equipment, or other property belonging
to the Company, and you shall also return all writings, files, records, correspondence, notebooks, notes and other documents and things
(including any copies thereof) containing confidential information or relating to the business or proposed business of the Company or
its affiliated entities or containing any trade secrets relating to the Company or its affiliated entities. For purposes of the preceding
sentence, the term “trade secrets” shall have the meaning ascribed to it under the Uniform Trade Secrets Act. You agree to
represent in writing to the Company upon termination of employment that you have complied with the foregoing provisions of this Section.

 

14.             
Assistance with Claims: You agree that, consistent with your business and personal affairs,
during and after your employment by the Company, you will assist the Company and its affiliated entities in the defense of any claims,
or potential claims that may be made or are threatened to be made against any of them in any action, suit or proceeding, whether civil,
criminal, administrative or investigative (a “Proceeding”), and will assist the Company and its affiliated entities
in the prosecution of any claims that may be made by the Company or its affiliated entities in any Proceeding, to the extent that such
claims may relate to your employment or the period of your employment by the Company. The Company agrees to reimburse you for your reasonable
out-of-pocket expenses associated with such assistance, including travel expenses. Any amounts to be paid to you pursuant to this Section 15
shall be paid by the Company within no later than thirty (30) days of the date on which you provide documentation to the Company
that such expenses were incurred.

 

     

    	Michael Doyle
 Employment Agreement
 Page 9	 

    

 

15.             
Representation Regarding Other Obligations: This offer is conditioned on your representation that you are not subject
to any confidentiality, non-competition agreement or any other similar type of restriction that may affect your ability to devote full
time and attention to your work at the Company. If you have entered into any agreement that may restrict your activities on behalf of
the Company, please provide me with a copy of the agreement as soon as possible.

 

16.             
Restrictive Covenants: You will be required to sign the Company’s standard “Employee Non-Competition,
Non-Solicitation, Confidentiality and Assignment Agreement” as a condition of your employment. A copy of that Agreement is enclosed.
If the Company elects to enforce a non-competition provision for which post-employment payments are required
under applicable law (“Non-Competition Payment”), the Company may apply the amount of any Non-Competition Payment to
the Termination Benefits.

 

17.             
Other Terms: Your employment with the Company shall be on an at-will basis. In other words, you or the Company may
terminate employment for any reason and at any time, with or without notice. In addition, as with all employees, our offer to you is contingent
on your submission of satisfactory proof of your identity and your legal authorization to work in the United States.

 

We are excited about the opportunity to work with you at Quanterix.
If you have any questions about this information, please do not hesitate to call. Otherwise, please confirm your acceptance of this offer
of employment by signing below and returning a copy to me no later than June 18, 2021.

 

We are confident that with your background and skills, you
will have an immediate positive impact on our organization.

 

[Signature Page Follows]

     

    	Michael Doyle
 Employment Agreement
 Page 10	 

    

  

Sincerely,

 

/s/ Kevin Hrusovsky

 

Kevin Hrusovsky

CEO and Executive Chairman

 

AGREED TO AND ACCEPTED

 

 

	/s/
    Michael Doyle	 	 
	Michael Doyle

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00329-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00329-of-00352.parquet"}]]